Rapid AST Advantage First Light Diagnostics offers rapid antimicrobial susceptibility testing using MultiPath technology, enabling pathogen detection and targeted antibiotics in hours rather than days. For sales teams, position to hospital labs and infectious disease departments seeking faster results to improve patient outcomes, shorten hospital stays, and support antibiotic stewardship programs. Recommend pilots or validation studies to showcase ROI.

Strategic Partnerships As a small but funded medtech firm, they can scale through partnerships with hospital systems, clinical reference labs, and distributors. Opportunity to pursue regional hospital networks in the Northeast, GI, or critical care sectors, plus OEM or co-development channels with larger manufacturers or distributors to broaden reach and manufacturing capacity.

Stewardship Alignment The product aligns with nationwide antibiotic stewardship initiatives; healthcare buyers are prioritizing rapid susceptibility testing to guide therapy quickly. Sales approach: tie product benefits to stewardship metrics, reduced antibiotic days, and improved stewardship compliance; propose clinical collaborations with ID physicians and pharmacy leadership to build case studies.

Public Lab Focus Potential to pursue public health labs, federal procurement, and research institutions needing rapid, cost-effective diagnostics. Position as a complement to large lab networks and as a niche provider for rapid AST; suggest pursuing grant-based collaborations or contract research opportunities to expand adoption.

Growth Readiness With modest revenue and external funding, the company is positioned for co-development, licensing, or OEM deals with larger medtech players. Approach large incumbents in diagnostics for distribution, manufacturing scale, and integration with existing platforms, offering a more complete diagnostic workflow.